Company Description
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria.
The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Country | United States |
Founded | 2020 |
IPO Date | May 5, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 51 |
CEO | Dr. Shao-Lee Lin M.D., Ph.D. |
Contact Details
Address: 4149 Liberty Canyon Rd. Agoura Hills, California 91301 United States | |
Phone | 805-871-4300 |
Website | acelyrin.com |
Stock Details
Ticker Symbol | SLRN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001962918 |
ISIN Number | US00445A1007 |
Employer ID | 85-2406735 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Shao-Lee Lin M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
Melanie Gloria B.S.N. | Chief Operating Officer |
Gilbert M. Labrucherie J.D. | Chief Financial Officer, Principal Financial Officer and principal accounting officer |
Mina Kim | Chief Legal and Administrative Officer |
Tyler Marciniak | Head of Investor Relations and Communications |
Ron Oyston | Chief People Officer |
Dr. Paul M. Peloso M.D., M.Sc. | Chief Medical Officer |
Suzy Buckhalter CPA | Senior Director of Finance and Accounting |
Kenneth A. Lock | Chief Commercial Officer |
Dr. Shephard Mpofu M.D. | Senior Vice President of Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 28, 2024 | 10-K | Annual Report |
Mar 28, 2024 | 8-K | Current Report |
Mar 20, 2024 | 144 | Filing |
Mar 20, 2024 | 8-K | Current Report |
Mar 11, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |